Nitrazepam Genethics Europe (Nitrazepam)

Nitrazepam binds to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This increases the frequency of chloride channel opening when GABA binds, leading to greater neuronal inhibition and producing its anxiolytic, sedative‑hypnotic, and anticonvulsant effects.

The exact dose of nitrazepam is determined by the prescribing clinician based on the individual’s medical condition, age, liver function, and response to therapy. Dosage regimens are tailored to each patient and should follow the prescriber’s instructions without deviation.

The safety of nitrazepam in pregnancy and lactation has not been established. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nitrazepam shares the core mechanism of GABA‑A modulation with other benzodiazepines but is distinguished by its relatively long half‑life, which can provide sustained sleep‑inducing effects. Compared with shorter‑acting agents, it may be preferred for chronic insomnia but requires careful monitoring for accumulation and daytime sedation.

Nitrazepam tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and light. Maintaining a stable environment helps preserve potency and prevents degradation over the product’s shelf life.

Nitrazepam is administered orally, typically as a tablet taken with a glass of water. The exact timing (e.g., before bedtime for insomnia) and dosing schedule are determined by the prescriber based on the therapeutic indication and patient needs.

Serious risks include respiratory depression, especially when combined with other depressants, severe allergic reactions, and the potential for dependence, tolerance, or withdrawal symptoms upon abrupt discontinuation. Patients should be monitored closely for these events, and any concerning signs should prompt immediate medical evaluation.

Nitrazepam is contraindicated in individuals with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients who are currently abusing alcohol or other central nervous system depressants. It should also be used with caution in those with severe hepatic impairment.